These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 26513202)

  • 1. A randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of venlafaxine extended release and a long-term extension study for patients with major depressive disorder in Japan.
    Higuchi T; Kamijima K; Nakagome K; Itamura R; Asami Y; Kuribayashi K; Imaeda T
    Int Clin Psychopharmacol; 2016 Jan; 31(1):8-19. PubMed ID: 26513202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A meta-analysis of the efficacy of venlafaxine extended release 75-225 mg/day for the treatment of major depressive disorder.
    Thase M; Asami Y; Wajsbrot D; Dorries K; Boucher M; Pappadopulos E
    Curr Med Res Opin; 2017 Feb; 33(2):317-326. PubMed ID: 27794623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.
    Gelenberg AJ; Lydiard RB; Rudolph RL; Aguiar L; Haskins JT; Salinas E
    JAMA; 2000 Jun; 283(23):3082-8. PubMed ID: 10865302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
    J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder.
    Fagiolini A; Albert U; Ferrando L; Herman E; Muntean C; Pálová E; Cattaneo A; Comandini A; Di Dato G; Di Loreto G; Olivieri L; Salvatori E; Tongiani S; Kasper S
    Int Clin Psychopharmacol; 2020 May; 35(3):137-146. PubMed ID: 31972628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder.
    Thase ME; Kornstein SG; Germain JM; Jiang Q; Guico-Pabia C; Ninan PT
    CNS Spectr; 2009 Mar; 14(3):144-54. PubMed ID: 19407711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials.
    Katz IR; Reynolds CF; Alexopoulos GS; Hackett D
    J Am Geriatr Soc; 2002 Jan; 50(1):18-25. PubMed ID: 12028242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression.
    Rudolph RL; Fabre LF; Feighner JP; Rickels K; Entsuah R; Derivan AT
    J Clin Psychiatry; 1998 Mar; 59(3):116-22. PubMed ID: 9541154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression.
    Rudolph RL; Feiger AD
    J Affect Disord; 1999 Dec; 56(2-3):171-81. PubMed ID: 10701474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression.
    Schatzberg A; Roose S
    Am J Geriatr Psychiatry; 2006 Apr; 14(4):361-70. PubMed ID: 16582045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.
    Rickels K; Pollack MH; Sheehan DV; Haskins JT
    Am J Psychiatry; 2000 Jun; 157(6):968-74. PubMed ID: 10831478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group.
    Cunningham LA
    Ann Clin Psychiatry; 1997 Sep; 9(3):157-64. PubMed ID: 9339881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of venlafaxine extended release in major depressive disorder patients: effect of baseline anxiety symptom severity.
    Lyndon GJ; Prieto R; Wajsbrot DB; Allgulander C; Bandelow B
    Int Clin Psychopharmacol; 2019 May; 34(3):110-118. PubMed ID: 30870236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial.
    Boyer P; Montgomery S; Lepola U; Germain JM; Brisard C; Ganguly R; Padmanabhan SK; Tourian KA
    Int Clin Psychopharmacol; 2008 Sep; 23(5):243-53. PubMed ID: 18703933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind comparison of venlafaxine and amitriptyline in outpatients with major depression with or without melancholia.
    Gentil V; Kerr-Correa F; Moreno R; D'Arrigo Busnello E; De Campos JA; Juruena MF; Lafer B; Moreno DH; De Cassia Rodrigues RL; Tiosso A; Benedictis E
    J Psychopharmacol; 2000 Mar; 14(1):61-6. PubMed ID: 10757255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors impacting the efficacy of venlafaxine extended release 75-225 mg/day in patients with major depressive disorder: exploratory post hoc subgroup analyses of a randomized, double-blind, placebo-controlled study in Japan.
    Watanabe Y; Asami Y; Hirano Y; Kuribayashi K; Itamura R; Imaeda T
    Neuropsychiatr Dis Treat; 2018; 14():1261-1272. PubMed ID: 29844674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the Psychometric Properties and Responsiveness to Change of 3 Depression Measures in a Sample of Persons With Traumatic Spinal Cord Injury and Major Depressive Disorder.
    Williams RT; Heinemann AW; Neumann HD; Fann JR; Forchheimer M; Richardson EJ; Bombardier CH;
    Arch Phys Med Rehabil; 2016 Jun; 97(6):929-37. PubMed ID: 26859610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of venlafaxine in the treatment of bipolar II major depressive episode.
    Amsterdam J
    J Clin Psychopharmacol; 1998 Oct; 18(5):414-7. PubMed ID: 9790160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.